Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Genetic loss of Tmprss6 alters terminal erythroid differentiation in a mouse model of β-thalassemia intermedia.

Stagg DB, Whittlesey RL, Li X, Lozovatsky L, Gardenghi S, Rivella S, Finberg KE.

Haematologica. 2019 Oct;104(10):e442-e446. doi: 10.3324/haematol.2018.213371. Epub 2019 Feb 28. No abstract available.

2.

Androgen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancer.

Norris JD, Ellison SJ, Baker JG, Stagg DB, Wardell SE, Park S, Alley HM, Baldi RM, Yllanes A, Andreano KJ, Stice JP, Lawrence SA, Eisner JR, Price DK, Moore WR, Figg WD, McDonnell DP.

J Clin Invest. 2017 Jun 1;127(6):2326-2338. doi: 10.1172/JCI87328. Epub 2017 May 2.

3.

Inhibiting androgen receptor nuclear entry in castration-resistant prostate cancer.

Pollock JA, Wardell SE, Parent AA, Stagg DB, Ellison SJ, Alley HM, Chao CA, Lawrence SA, Stice JP, Spasojevic I, Baker JG, Kim SH, McDonnell DP, Katzenellenbogen JA, Norris JD.

Nat Chem Biol. 2016 Oct;12(10):795-801. doi: 10.1038/nchembio.2131. Epub 2016 Aug 8.

4.

Small-Molecule-Mediated Degradation of the Androgen Receptor through Hydrophobic Tagging.

Gustafson JL, Neklesa TK, Cox CS, Roth AG, Buckley DL, Tae HS, Sundberg TB, Stagg DB, Hines J, McDonnell DP, Norris JD, Crews CM.

Angew Chem Int Ed Engl. 2015 Aug 10;54(33):9659-62. doi: 10.1002/anie.201503720. Epub 2015 Jun 17.

Supplemental Content

Loading ...
Support Center